Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

Authors

Jay Parekh, Yale New Haven Health System, Bridgeport Hospital, Bridgeport, CT, USA.
Kaushal Parikh, Mayo Clinic, Rochester, MN, USA.
Joshua E. Reuss, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Alex Friedlaender, Clinique General Beaulieu, Geneva, Switzerland.
Alfredo Addeo, University Hospital Geneva, Geneva, Switzerland. alfredo.addeo@hcuge.ch.

Document Type

Article

Publication Title

Current oncology reports

Abstract

PURPOSE OF REVIEW: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates. RECENT FINDINGS: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with recent approvals in the peri-operative space, is now poised to transform the systemic treatment paradigm for localized and locally-advanced NSCLC. In this review, we focus on neoadjuvant ICB in resectable NSCLC, highlighting the pre-clinical rationale for neoadjuvant ICB, early clinical trials, randomized phase 3 trial data, and future directions for resectable NSCLC.

First Page

913

Last Page

922

DOI

10.1007/s11912-023-01430-4

Publication Date

8-1-2023

Recommended Citation

Parekh, Jay; Parikh, Kaushal; Reuss, Joshua E.; Friedlaender, Alex; and Addeo, Alfredo, "Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer" (2023). Randomized Controlled Trial. 7.
https://scholar.bridgeporthospital.org/randomized_trial/7

Identifier

37249833 (pubmed); PMC10326100 (pmc); 10.1007/s11912-023-01430-4 (doi); 10.1007/s11912-023-01430-4 (pii)